La catena delle opzioni mostra i dati chiave delle opzioni azionarie di FOXO Technologies a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per FOXO Technologies..

FOXO Technologies (AMEX:FOXO) Azioni, Catena delle Opzioni

FOXO Technologies

FOXO Technologies Inc is a technology platform company focused on commercializing longevity science through products and services that serve the life insurance industry. FOXO's epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. The company has two reportable business segments, FOXO Labs and FOXO Life.

FOXO Technologies Inc. Class A Common Stock

FOXO Technologies Inc

FOXO Technologies Inc Warrants (01/08/2027)

Hillman Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HLMN#NASDAQ">HLMN</a>) reported quarterly earnings of $0.16 per share which met the analyst consensus estimate. The company reported quarterly sales of $393.300 million which beat the analyst consensus estimate of $387.780 million by 1.42 percent. This is a 1.41 percent decrease over sales of $398.943 million the same period last year.

Earnings

Earnings Beats

News

HLMN

Hillman Solutions Q3 2024 Adj. EPS $0.16, Inline, Sales $393.300M Beat $387.780M Estimate

Guidance

LIND

Lindblad Expeditions Continues To See FY24 Tour Revenues Of $610M - $630M (Est $622.65M), Adjusted EBITDA  Of $88M - $98M

Karyopharm Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KPTI#NASDAQ">KPTI</a>) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 13.33 percent increase over losses of $(0.30) per share from the same period last year. The company reported quarterly sales of $38.78 million which beat the analyst consensus estimate of $37.79 million by 2.63 percent. This is a 7.70 percent increase over sales of $36.01 million the same period last year.

KPTI

Karyopharm Therapeutics Q3 2024 GAAP EPS $(0.26), Inline, Sales $38.78M Beat $37.79M Estimate

Cummins (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMI#NYSE">CMI</a>) reported quarterly earnings of $5.86 per share which beat the analyst consensus estimate of $4.78 by 22.59 percent. This is a 27.67 percent increase over earnings of $4.59 per share from the same period last year. The company reported quarterly sales of $8.456 billion which beat the analyst consensus estimate of $8.294 billion by 1.96 percent. This is a 0.30 percent increase over sales of $8.431 billion the same period last year.

Cummins Q3 2024 GAAP EPS $5.86 Beats $4.78 Estimate, Sales $8.456B Beat $8.294B Estimate

Loop Capital analyst Rick Paterson downgrades Air Transport Services Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) from Buy to Hold and raises the price target from $22 to $22.5.

Downgrades

Price Target

Analyst Ratings

ATSG

Loop Capital Downgrades Air Transport Services Gr to Hold, Raises Price Target to $22.5

PAYO

Payoneer Global Q3 2024 GAAP EPS $0.11 Beats $0.04 Estimate, Sales $248.274M Beat $225.476M Estimate

Biotech

Health Care

General

The FDA Has Extended The Target Action Date Of Its Review Of Organon's Supplemental New Drug Application For Vtama (Tapinarof) Cream, 1% For Atopic Dermatitis In Adults And Children Two Years Of Age And Older. The New Target Date Is March 12, 2025, Revised From The Original Target Action Date Of December 12

Baird analyst Tristan Gerra maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Outperform and lowers the price target from $70 to $44.

LSCC

Baird Maintains Outperform on Lattice Semiconductor, Lowers Price Target to $44

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58407d80aae83900016b3bd0/bryan-keane">Deutsche Bank analyst Bryan Keane</a> downgraded the rating for Marqeta, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MQ#NASDAQ">MQ</a>) from Buy to Hold and lowered the price target from $9 to $4. Marqeta shares closed at $5.95 on Monday. <a href="https://www.benzinga.com/quote/MQ/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Truist Securities analyst Jamie Cook downgraded Cognex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) from Buy to Hold and slashed the price target from $46 to $43. Cognex shares closed at $40.85 on Monday. <a href="https://www.benzinga.com/quote/CGNX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JMP Securities analyst Reni Benjamin downgraded the rating for Sana Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SANA#NASDAQ">SANA</a>) from Market Outperform to Market Perform. Sana Biotechnology shares closed at $3.76 on Monday. <a href="https://www.benzinga.com/quote/SANA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/603e4f87b3e2040001080043/tessa-romero">JP Morgan analyst Tessa Romero</a> downgraded Neumora Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRA#NASDAQ">NMRA</a>) from Overweight to Neutral and lowered the price target from $18 to $15. Neumora Therapeutics shares closed at $11.71 on Monday. <a href="https://www.benzinga.com/quote/NMRA/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Leerink Partners analyst Christopher Liu downgraded the rating for IDEAYA Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IDYA#NASDAQ">IDYA</a>) from Outperform to Market Perform and lowered the price target from $41 to $27. IDEAYA Biosciences shares closed at $30.00 on Monday. <a href="https://www.benzinga.com/quote/IDYA/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CGNX stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="533" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png" alt="" class="wp-image-630098" style="width:676px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-1024x533.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27-768x400.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/05072904/image-27.png 1272w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/11/41740698/top-3-health-care-stocks-youll-regret-missing-in-november">Top 3 Health Care Stocks You&#8217;ll Regret Missing In November</a></li>
</ul>

Pre-Market Outlook

Markets

Trading Ideas

CGNX

IDYA

NMRA

SANA

This Cognex Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Keybanc analyst John Vinh maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Overweight and lowers the price target from $60 to $54.

Keybanc Maintains Overweight on Lattice Semiconductor, Lowers Price Target to $54

Baird analyst David Koning maintains Fidelity National Info (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) with a Neutral and raises the price target from $92 to $94.

Baird Maintains Neutral on Fidelity National Info, Raises Price Target to $94

Lindblad Expeditions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIND#NASDAQ">LIND</a>) reported quarterly earnings of $0.36 per share which beat the analyst consensus estimate of $0.20 by 80 percent. This is a 350 percent increase over earnings of $0.08 per share from the same period last year. The company reported quarterly sales of $206.00 million which beat the analyst consensus estimate of $193.80 million by 6.30 percent. This is a 17.06 percent increase over sales of $175.99 million the same period last year.

Lindblad Expeditions Q3 2024 GAAP EPS $0.36 Beats $0.20 Estimate, Sales $206.00M Beat $193.80M Estimate

In 2018, the International Brotherhood of Electrical Workers Local 38 Health and Welfare Fund and some consumers filed a proposed class action lawsuit against Walgreens Boots Alliance Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>).
The plaintiffs <a target="_blank" href="https://cases.justia.com/federal/district-courts/illinois/ilndce/1:2017cv02246/338055/91/0.pdf?ts=1520678017" rel="noreferrer noopener">alleged</a> that the retail pharmacy engaged in deceptive pricing practices through its Prescription Savings Club (PSC)—a program offering discounted prices on generic drugs for customers who pay without insurance.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41366045/walgreens-boots-alliance-analysts-expect-strategic-plans-will-boost-investor-confid" rel="noreferrer noopener">Walgreens Boots Alliance Analysts Expect Strategic Plans Will Boost Investor Confidence In 2025</a>
Plaintiffs claim these practices led Walgreens to inflate the &#8220;usual and customary&#8221; (U&amp;C) prices reported to health insurers and third-party payors, resulting in customers overpaying for generic drugs.
Reuters noted that Walgreens&nbsp;has agreed to pay $100 million to settle a proposed class action lawsuit.
Reuters cited a Walgreens spokesperson and noted that the company accepts no liability and maintains that these claims are without merit.
Walgreens introduced its Prescription Savings Club (PSC) in 2007, offering over 500 commonly prescribed generic medications at reduced prices: $5, $10, or $15 for 30-day supplies, and $10, $20, or $30 for 90-day supplies, depending on the drug&#8217;s tier. Enrollment in the PSC requires a yearly fee of $20 for individuals or $30 per family.
The complaint asserts that while Walgreens offered these lower PSC prices to cash-paying customers, it charged higher prices for the same drugs to customers using private insurance, Medicare, or Medicaid. According to the plaintiffs, Walgreens&#8217; PSC prices should have been reported as its U&amp;C prices.
Instead, by reporting higher-than-PSC prices as U&amp;C prices on reimbursement claims, Walgreens allegedly engaged in a hidden dual-pricing scheme for drugs listed under the PSC.
Price Action: At last check Tuesday, WBA stock was up 0.21% at $9.35 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/24/11/41739764/taiwan-semiconductor-faces-rising-energy-costs-potential-outages-threaten-production" target="_blank" rel="noreferrer noopener">Taiwan Semiconductor Faces Rising Energy Costs, Potential Outages Threaten Production</a></li>
</ul>
Photo via Shutterstock

Large Cap

Legal

Walgreens Agrees To $100 Million Settlement Over Alleged Deceptive Pricing Of Generic Drugs

Barclays analyst George Wang initiates coverage on Celestica (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLS#NYSE">CLS</a>) with a Overweight rating and announces Price Target of $91.

Initiation

Barclays Initiates Coverage On Celestica with Overweight Rating, Announces Price Target of $91

NeoGenomics Reiterates FY24 Revenue Outlook In The Range Of $655M-$667M; Raises Adjusted EBITDA Guidance From $33M-$37M To $37M-$40M

AdaptHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHCO#NASDAQ">AHCO</a>) reported quarterly sales of $805.86 million which missed the analyst consensus estimate of $809.30 million by 0.43 percent. This is a 0.23 percent increase over sales of $804.03 million the same period last year.

Earnings Misses

AHCO

AdaptHealth Q3 Sales $805.86M Miss $809.30M Estimate

TRDA

Entrada Therapeutics Says Cash Runway Expected Into 2027 With $449M In Cash, Cash Equivalents And Marketable Securities As Of September 30, 2024

Entrada Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRDA#NASDAQ">TRDA</a>) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0.78) by 55.13 percent. The company reported quarterly sales of $19.57 million which beat the analyst consensus estimate of $12.32 million by 58.83 percent. This is a 55.25 percent decrease over sales of $43.73 million the same period last year.

Entrada Therapeutics Q3 2024 GAAP EPS $(0.35) Beats $(0.78) Estimate, Sales $19.57M Beat $12.32M Estimate

By <a href="https://roboforex.com/beginners/analytics/forex-forecast/?utm_source=benzinga.com&amp;utm_medium=pr&amp;utm_campaign=rf_en_external_article_05112024&amp;utm_content=analysis&amp;utm_term=forecast" style="color:#0563c1; text-decoration:underline">RoboForex Analytical Department</a>
EURUSD remains poised around 1.0878 as markets brace for the outcome of the highly anticipated US presidential election. With the world watching, the direction of the major currency pair will hinge significantly on the election results, where a victory for Donald Trump is likely to bolster the USD, potentially leading to a notable increase. Conversely, a win for Kamala Harris could see the USD decline by an average of 1-2%.
The impending volatility is not solely due to the election but amplified by the upcoming Federal Reserve meeting scheduled for Wednesday. The Fed is anticipated to cut interest rates slightly by 25 basis points. Market participants are keenly awaiting any forward guidance from the Fed, particularly with expectations leaning towards another rate reduction in December.
While significant economic data releases are also expected, these pivotal events may overshadow their impact.
<h3>Technical Analysis Of EUR/USD</h3>
<a href="https://www.benzinga.com/files/u117641/eurusdh4_71.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh4_71.png" style="height:280px; width:624px" /></a>
The EURUSD market has completed a growth structure reaching 1.0913, considered part of a third growth wave targeting 1.0950. After this target is achieved, a retraction to 1.0860 is anticipated, potentially forming a broad consolidation range around this level. Technical indicators, such as the MACD, suggest an upward trajectory, reinforcing the possibility of reaching 1.0960 before a corrective pullback to 1.0860.
<a href="https://www.benzinga.com/files/u117641/eurusdh1_72.png"><img alt="" src="https://www.benzinga.com/files/u117641/eurusdh1_72.png" style="height:280px; width:624px" /></a>
Support at 1.0872 has spurred the development of a growth impulse towards 1.0900, which is expected to be tested soon. Breaching this level could extend the growth wave towards 1.0950. The Stochastic oscillator supports this short-term forecast, indicating upward momentum with its signal line targeting the upper echelons around 80.
Disclaimer
Any forecasts contained herein are based on the author&#39;s particular opinion. This analysis may not be treated as trading advice. RoboForex bears no responsibility for trading results based on trading recommendations and reviews contained herein.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Technicals

Forex

EUR/USD Stabilises As US Presidential Election Unfolds

Leerink Partners analyst Mani Foroohar initiates coverage on Camp4 Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) with a Outperform rating and announces Price Target of $17.

CAMP

Leerink Partners Initiates Coverage On Camp4 Therapeutics with Outperform Rating, Announces Price Target of $17

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
FOXO Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/foxo-stock-quote/">FOXO</a>) just reported results for the fourth quarter of 2023.<ul><li>FOXO Technologies reported earnings per share of 40 cents.</li><li>The company reported revenue of $110,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/foxo-stock-earnings-foxo-technologies-for-q4-of-2023/">FOXO Stock Earnings: FOXO Technologies Reported Results for Q4 2023</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FOXO Stock Earnings: FOXO Technologies Reported Results for Q4 2023

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
FOXO Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/foxo-stock-quote/">FOXO</a>) just reported results for the first quarter of 2024.<ul><li>FOXO Technologies reported earnings per share of -24 cents.</li><li>The company reported revenue of $7,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/foxo-stock-earnings-foxo-technologies-for-q1-of-2024/">FOXO Stock Earnings: FOXO Technologies Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FOXO Stock Earnings: FOXO Technologies Reported Results for Q1 2024

FOXO Technologies regains compliance with SEC reporting requirements

FOXO announces receipt of non-compliance notice with NYSE

An update from FOXO Technologies (FOXO) is now available. FOXO Technologies Inc. has engaged in strategic partnerships and agreements to enhance it...

FOXO Technologies Bolsters Expertise and Leadership Team

FOXO Technologies (FOXO) has shared an update. FOXO Technologies Inc. has engaged in a series of financial agreements with ClearThink Capital Partn...

FOXO Technologies Adjusts Financial Agreements with ClearThink

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
FOXO Technologies (NYSEMKT:<a href="https://investorplace.com/stock-quotes/foxo-stock-quote/">FOXO</a>) just reported results for the second quarter of 2024.<ul><li>FOXO Technologies reported earnings per share of -24 cents.</li><li>The company reported revenue of $28,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/foxo-stock-earnings-foxo-technologies-for-q2-of-2024/">FOXO Stock Earnings: FOXO Technologies Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FOXO Stock Earnings: FOXO Technologies Reported Results for Q2 2024

FOXO Technologies ( ($FOXO) ) has shared an announcement. Rennova Health, Inc. and its subsidiary engaged in a strategic transaction involving a st...

FOXO Technologies Announces Strategic Transaction and Board Expansion

An update from FOXO Technologies ( ($FOXO) ) is now available. FOXO Technologies, a pioneer in epigenetic biomarker discovery, has had a transforma...

FOXO Technologies Advances in AI-Driven Healthcare Growth

FOXO Technologies ( ($FOXO) ) has provided an announcement. FOXO Technologies Inc. has issued a new Series A Cumulative Convertible Redeemable Pref...

FOXO Technologies Issues New Stock and Negotiates Debt

FOXO

Press Releases

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance  with NYSE Continued Listing Requirements

FOXO Technologies Enters into Share Exchange Agreements to Acquire Healthcare Operations from Rennova Health, Inc.

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements; Completes Steps it Believes are Required to Regain Compliance

RENNOVA HEALTH, INC. ANNOUNCES STOCK EXCHANGE AGREEMENTS WITH FOXO TECHNOLOGIES, INC. FOR TWO OPERATING SUBSIDIARIES

FOXO Technologies Inc. Secures Up to $2.8 Million in Senior Notes to Fund Previously Announced Acquisition of Myrtle Recovery Centers, Inc. and Provide Additional Working Capital

Foxo Technologies, Inc., Regains Compliance with SEC Reporting Requirements

FOXO Technologies Inc. Announces Receipt of Notice of Non-Compliance with NYSE Continued Listing Requirements

FOXO Technologies Subsidiary, Myrtle Recovery Centers, Receives Two Full Licenses from the Tennessee Department of Mental Health and Substance Abuse Services

Comments

FOXO Technologies

FOXO Technologies (FOXO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO